Eli Lilly Debt to Equity Ratio 2006-2018 | LLY

Current and historical debt to equity ratio values for Eli Lilly (LLY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Eli Lilly debt/equity for the three months ending December 31, 2018 was 0.83.
Eli Lilly Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-12-31 $0.00B $0.00B 0.00
2018-09-30 $11.68B $14.15B 0.83
2018-06-30 $9.17B $11.62B 0.79
2018-03-31 $9.39B $14.59B 0.64
2017-12-31 $9.94B $11.67B 0.85
2017-09-30 $9.93B $14.96B 0.66
2017-06-30 $9.87B $14.17B 0.70
2017-03-31 $7.64B $14.10B 0.54
2016-12-31 $8.37B $14.08B 0.59
2016-09-30 $8.71B $15.62B 0.56
2016-06-30 $8.69B $14.66B 0.59
2016-03-31 $7.48B $15.03B 0.50
2015-12-31 $7.97B $14.59B 0.55
2015-09-30 $8.07B $15.24B 0.53
2015-06-30 $7.99B $14.71B 0.54
2015-03-31 $7.42B $14.95B 0.50
2014-12-31 $5.33B $15.39B 0.35
2014-09-30 $5.29B $17.68B 0.30
2014-06-30 $5.30B $18.00B 0.30
2014-03-31 $5.26B $18.35B 0.29
2013-12-31 $4.20B $17.64B 0.24
2013-09-30 $4.26B $16.90B 0.25
2013-06-30 $4.29B $15.24B 0.28
2013-03-31 $4.43B $14.96B 0.30
2012-12-31 $5.52B $14.77B 0.37
2012-09-30 $5.51B $16.06B 0.34
2012-06-30 $5.50B $14.31B 0.38
2012-03-31 $5.40B $14.82B 0.37
2011-12-31 $5.47B $13.54B 0.40
2011-09-30 $5.45B $15.06B 0.36
2011-06-30 $5.20B $14.28B 0.36
2011-03-31 $5.13B $13.93B 0.37
2010-12-31 $6.77B $12.41B 0.55
2010-09-30 $6.98B $12.41B 0.56
2010-06-30 $6.86B $10.24B 0.67
2010-03-31 $6.66B $10.46B 0.64
2009-12-31 $6.64B $9.53B 0.70
2009-09-30 $6.77B $9.91B 0.68
2009-06-30 $6.69B $8.56B 0.78
2009-03-31 $6.87B $7.73B 0.89
2008-12-31 $4.62B $6.74B 0.69
2008-09-30 $4.19B $13.74B 0.31
2008-06-30 $4.55B $14.74B 0.31
2008-03-31 $4.65B $14.91B 0.31
2007-12-31 $4.59B $13.50B 0.34
2007-09-30 $4.53B $12.95B 0.35
2007-06-30 $4.57B $11.56B 0.40
2007-03-31 $4.62B $11.53B 0.40
2006-12-31 $3.49B $10.98B 0.32
2006-09-30 $4.55B $13.06B 0.35
2006-06-30 $5.58B $11.93B 0.47
2006-03-31 $5.61B $11.69B 0.48
2005-12-31 $5.76B $10.79B 0.53
2005-09-30 $5.88B $11.38B 0.52
2005-06-30 $4.45B $10.27B 0.43
2005-03-31 $4.36B $11.60B 0.38
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $127.913B $24.556B
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $360.341B 16.42
Pfizer (PFE) United States $249.842B 13.99
Merck (MRK) United States $212.837B 18.19
Novartis AG (NVS) Switzerland $205.636B 17.49
Novo Nordisk (NVO) Denmark $121.639B 19.68
AbbVie (ABBV) United States $121.119B 10.18
Sanofi (SNY) France $104.236B 12.87
GlaxoSmithKline (GSK) United Kingdom $101.357B 13.31
AstraZeneca (AZN) United Kingdom $101.265B 11.56
Bristol-Myers Squibb (BMY) United States $82.965B 12.77